Surgery plus adjuvant radiotherapy for primary central nervous system lymphoma

References

• O’neill BP, Decker PA, Tieu C, Cerhan JR. The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin’s lymphoma. Am J Hematol 2013;88:997–1000.
   PubMed Web of Science ®Google Scholar
• Schabet M. Epidemiology of primary CNS lymphoma. J Neurooncol 1999;43:199–201.
   PubMed Web of Science ®Google Scholar
• Shiels MS, Pfeiffer RM, Besson C, et al. Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol 2016;174:417–24.
   PubMed Web of Science ®Google Scholar
• Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008;123:187–94.
   PubMed Web of Science ®Google Scholar
• Villano JL, Koshy M, Shaikh H, Dolecek TA, Mccarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 2011;105:1414–8.
   PubMed Web of Science ®Google Scholar
• Van Der Meulen M, Dinmohamed AG, Visser O, Doorduijn JK, Bromberg JEC. Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the netherlands. Leukemia 2017;31:1989–2015.
   PubMed Web of Science ®Google Scholar
• Citterio G, Ferreri AJ, Reni M. Current uses of radiation therapy in patients with primary CNS lymphoma. Expert Rev Anticancer Ther 2013;13:1327–37.
   PubMed Web of Science ®Google Scholar
• Milgrom SA, Yahalom J. The role of radiation therapy in the management of primary central nervous system lymphoma. Leuk Lymph 2015;56:1197–204.
   PubMed Web of Science ®Google Scholar
• Deangelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93-10. JCO 2002;20:4643–8.
   PubMed Web of Science ®Google Scholar
• Fallah J, Qunaj L, Olszewski AJ. Therapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the national cancer database. Blood Adv 2016;1:112–21.
   PubMed Web of Science ®Google Scholar
• Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994;81:188–95.
   PubMed Web of Science ®Google Scholar
• Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. JCO 2013;31:3971–9.
   PubMed Web of Science ®Google Scholar
• Norden AD, Drappatz J, Wen PY, Claus EB. Survival among patients with primary central nervous system lymphoma, 1973–2004. J Neurooncol 2011;101:487–93.
   PubMed Web of Science ®Google Scholar
• Omuro AM, Ben-Porat LS, Panageas KS, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 2005;62:1595–600.
   PubMed Web of Science ®Google Scholar
• Shibamoto Y, Ogino H, Suzuki G, et al. Primary central nervous system lymphoma in Japan: changes in clinical features, treatment, and prognosis during 1985–2004. Neuro Oncol 2008;10:560–8.
   PubMed Web of Science ®Google Scholar
• Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (g-pcnsl-sg-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010;11:1036–47.
   PubMed Web of Science ®Google Scholar
• Pulido JS, Vierkant RA, Olson JE, Abrey L, Schiff D, O’Neill BP. Racial differences in primary central nervous system lymphoma incidence and survival rates. Neuro Oncol 2009;11:318–22.
   PubMed Web of Science ®Google Scholar
• Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57:495–504.
   PubMed Web of Science ®Google Scholar
• Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA 2012;308:1881–8.
   PubMed Web of Science ®Google Scholar
• Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190–8.
   PubMed Web of Science ®Google Scholar
• Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the glioma outcomes project. J Neurosurg 2003;99:467–73.
   PubMed Web of Science ®Google Scholar
• Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494–500.
   PubMed Web of Science ®Google Scholar
• Sanai N, Berger MS. Extent of resection influences outcomes for patients with gliomas. Rev Neurol (Paris) 2011;167:648–54.
   PubMed Web of Science ®Google Scholar
• Bataille B, Delwail V, Menet E, et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg 2000;92:261–6.
   PubMed Web of Science ®Google Scholar
• Bellinzona M, Roser F, Ostertag H, Gaab RM, Saini M. Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur J Surg Oncol 2005;31:100–5.
   PubMed Web of Science ®Google Scholar
• Berry MP, Simpson WJ. Radiation therapy in the management of primary malignant lymphoma of the brain. Int J Radiat Oncol Biol Phys 1981;7:55–9.
   PubMed Web of Science ®Google Scholar
• Caroli E, Acqui M, Ferrante L. Primary cerebral lymphoma: a retrospective study in 22 immunocompetent patients. Tumori 2004;90:294–8.
   PubMed Web of Science ®Google Scholar
• Davies KG, Cole GC, Weeks RD. Twenty-year survival following excision of primary CNS lymphoma without radiation therapy: case report. Br J Neurosurg 1994;8:487–91.
   PubMed Web of Science ®Google Scholar
• Deangelis LM, Yahalom J, Heinemann MH, Cirrincione C, Thaler HT, Krol G. Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology 1990;40:80–6.
   PubMed Web of Science ®Google Scholar
• Hayakawa T, Takakura K, Abe H, et al. Primary central nervous system lymphoma in Japan–a retrospective, co-operative study by CNS-lymphoma study group in japan. J Neuro-Oncol 1994;19:197–215.
   PubMed Web of Science ®Google Scholar
• Henry JM, Heffner RR, Jr., Dillard SH, Earle KM, Davis RL. Primary malignant lymphomas of the central nervous system. Cancer 1974;34:1293–302.
   PubMed Web of Science ®Google Scholar
• Jellinger K, Radaskiewicz TH, Slowik F. Primary malignant lymphomas of the central nervous system in man. Acta Neuropathol Suppl Suppl 1975;6:95–102.
   Google Scholar
• Murray K, Kun L, Cox J. Primary malignant lymphoma of the central nervous system. Results of treatment of 11 cases and review of the literature. J Neurosurg 1986;65:600–7.
   PubMed Web of Science ®Google Scholar
• Pollack IF, Lunsford LD, Flickinger JC, Dameshek HL. Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer 1989;63:939–47.
   PubMed Web of Science ®Google Scholar
• Sonstein W, Tabaddor K, Llena JF. Solitary primary CNS lymphoma: long term survival following total resection. Med Oncol 1998;15:61–5.
   PubMed Web of Science ®Google Scholar
• Tomlinson FH, Kurtin PJ, Suman VJ, et al. Primary intracerebral malignant lymphoma: a clinicopathological study of 89 patients. J Neurosurg 1995;82:558–66.
   PubMed Web of Science ®Google Scholar
• Cloney MB, Sonabend AM, Yun J, et al. The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis. J Neurooncol 2017;132:189–97.
   PubMed Web of Science ®Google Scholar
• Yun J, Yang J, Cloney M, et al. Assessing the safety of craniotomy for resection of primary central nervous system lymphoma: a nationwide inpatient sample analysis. Front Neurol 2017;8.
   Web of Science ®Google Scholar
• Jelicic J, Todorovic Balint M, Raicevic S, et al. The possible benefit from total tumour resection in primary diffuse large b-cell lymphoma of central nervous system – a one-decade single-centre experience. British Journal of Neurosurgery 2016;30:80–5.
   PubMed Web of Science ®Google Scholar
• Rae AI, Mehta A, Cloney M, et al. Craniotomy and survival for primary central nervous system lymphoma. Neurosurgery 2018;84:nyy096–nyy96.
   Web of Science ®Google Scholar
• Weller M, Martus P, Roth P, Thiel E, Korfel A; German PCNSL Study Group. Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol 2012;14:1481–4.
   PubMed Web of Science ®Google Scholar
• Bierman PJ. Surgery for primary central nervous system lymphoma: is it time for reevaluation? Oncology (Williston Park, N.Y.) 2014;28:632–7.
   PubMed Web of Science ®Google Scholar
• Yun J, Iwamoto FM, Sonabend AM. Primary central nervous system lymphoma: a critical review of the role of surgery for resection. Arch Cancer Res 2016;4.
   PubMedGoogle Scholar
• Davis FG, Mccarthy BJ, Berger MS. Centralized databases available for describing primary brain tumor incidence, survival, and treatment: central brain tumor registry of the United States; surveillance, epidemiology, and end results; and national cancer data base. Neuro-Oncology 1999;1:205–11.
   PubMedGoogle Scholar
• Kinslow CJ, Bruce SS, Rae AI, et al. Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study. J Neurooncol 2018;138:173–82.
   Google Scholar
• Boyett D, Kinslow CJ, Bruce SS, et al. Spinal location is prognostic of survival for solitary-fibrous tumor/hemangiopericytoma of the central nervous system. J Neuro-Oncol 2019;143: 457–64.
   Google Scholar
• Kinslow CJ, Garton ALA, Rae AI et al. Extent of resection and survival for oligodendroglioma: A U.S. Population-based study. J Neuro-Oncol 2019;144:591–601.
   Google Scholar
• Kinslow CJ, May MS, Saqi A, et al. Large-cell neuroendocrine carcinoma of the lung: A population-based study. Clin Lung Cancer 2019.
   Google Scholar
• Zhou Z, Kinslow CJ, Hibshoosh H, et al. Clinical features, survival and prognostic factors of glycogen-rich clear cell carcinoma (GRCC) of the breast in the U.S. Population. J Clin Med 2019;8:246.
   Google Scholar
• Zhou Z, Kinslow CJ, Wang P, et al. Clear cell adenocarcinoma of the urinary bladder is a glycogen-rich tumor with poorer prognosis. J Clin Med 2020;9:138.
   Google Scholar
• Overview of the Seer Program. 2016. National Cancer Institute Surveillance, Epidemiology, and End Results Program. 2016. NCCN clinical practice guidelines in oncology: Central nervous system cancers (version 1.2016): National Comprehensive Cancer Network. Released April 2016, based on the November 2015 submission. Surveillance, epidemiology, and end results (seer) program (http://www.Seer.Cancer.Gov) seer*stat database: Incidence – seer 9 regs research data, Nov 2015 sub (1973–2013) <katrina/rita population adjustment> – linked to county attributes – total U.S., 1969–2014 counties.
   Google Scholar
• Correa DD, Shi W, Abrey LE, et al. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro-oncology 2012;14:101–8.
   PubMed Web of Science ®Google Scholar
• Deangelis LM. Whither whole brain radiotherapy for primary CNS lymphoma? Neuro Oncology 2014;16:1032–4.
   PubMed Web of Science ®Google Scholar
• Weller M. The vanishing role of whole brain radiotherapy for primary central nervous system lymphoma. Neuro Oncol 2014;16:1035–6.
   PubMed Web of Science ®Google Scholar
• Correa DD, Rocco-Donovan M, Deangelis LM, et al. Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol 2009;91:315–21.
   PubMed Web of Science ®Google Scholar
• Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. JCO 2007;25:4730–5.
   PubMed Web of Science ®Google Scholar
• Mullenix PJ, Kernan WJ, Schunior A, et al. Interactions of steroid, methotrexate, and radiation determine neurotoxicity in an animal model to study therapy for childhood leukemia. Pediatr Res 1994;35:171–8.
   PubMed Web of Science ®Google Scholar
• Van Der Kogel AJ, Sissingh HA. Effects of intrathecal methotrexate and cytosine arabinoside on the radiation tolerance of the rat spinal cord. Radiother Oncol 1985;4:239–51.
   PubMed Web of Science ®Google Scholar
• Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe francaise de greffe de moelle osseuse-therapie cellulaire. JCO 2008;26:2512–8.
   PubMed Web of Science ®Google Scholar
• Lai R, Rosenblum MK, Deangelis LM. Primary CNS lymphoma: a whole-brain disease? Neurology 2002;59:1557–62.
   PubMed Web of Science ®Google Scholar
• Kinslow CJ, Rajpara RS, Wu C-C, et al. Invasiveness is associated with metastasis and decreased survival in hemangiopericytoma of the central nervous system. J Neurooncol 2017;133:1–9.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Lad SP, Herndon JE, 2nd, Starke RM, Kondziolka D. Seer insights. J Neurosurg 2014;120:297–8.
   PubMed Web of Science ®Google Scholar
• Sonabend AM, Zacharia BE, Goldstein H, et al. The role for adjuvant radiotherapy in the treatment of hemangiopericytoma: a surveillance, epidemiology, and end results analysis. JNS 2014;120:300–8.
   PubMed Web of Science ®Google Scholar
• Merrill RM, Capocaccia R, Feuer EJ, Mariotto A. Cancer prevalence estimates based on tumour registry data in the surveillance, epidemiology, and end results (seer) program. Int J Epidemiol 2000;29:197–207.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Yahalom J, Deangelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000;18:3144–50.
   PubMed Web of Science ®Google Scholar
• Sandor V, Stark-Vancs V, Pearson D, et al. Phase ii trial of chemotherapy alone for primary CNS and intraocular lymphoma. JCO 1998;16:3000–6.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Blay J-Y, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience. JCO 2003;21:266–72.
   PubMed Web of Science ®Google Scholar
• Yu JB, Gross CP, Wilson LD, Smith BD. Nci seer public-use data: applications and limitations in oncology research. Oncology (Williston Park, N.Y.) 2009;23:288–95.
   PubMed Web of Science ®Google Scholar
• Noone AM, Lund JL, Mariotto A, et al. Comparison of seer treatment data with medicare claims. Med Care 2016;54:e55–64.
   PubMed Web of Science ®Google Scholar
• Johnson SB, Park HS, Gross CP, Yu JB. Use of alternative medicine for cancer and its impact on survival. JNCI 2018;110:djx145–djx45.
   Google Scholar
• Warren JL, Harlan LC. Can cancer registry data be used to study cancer treatment? Med Care 2003;41:1003–5.
   PubMed Web of Science ®Google Scholar